Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice

Bhutta, Maimoona S; Sausen, Daniel G.; Reed, Kirstin M; Gallo, Elisa; Hair, Pamela S.; Lassiter, Brittany P.; Krishna, Neel K.; Cunnion, Kenji M.; Borenstein, Ronen

doi:10.3390/v13081422

Cited by 3 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding which viruses the interventions were tested on, 113 (82.48%) studies used HSV-1 [ 1 - 3 , 6 - 16 , 19 , 21 - 27 , 29 - 31 , 33 - 35 , 37 , 38 , 40 - 44 , 46 - 49 , 51 , 53 - 56 , 60 - 65 , 67 - 74 , 76 - 79 , 82 , 83 , 85 - 99 , 103 - 123 , 125 - 134 , 136 - 138 ], 61 (44.53%) studies used HSV-2 [ 7 - 11 , 14 - 20 , 25 , 27 , 28 , 30 - 33 , 35 - 37 , 39 , 44 - 53 , 55 , 58 , 59 , 61 , 66 , 69 , 73 , 75 , 81 , 83 , 85 , 89 , 91 , 93 , 100 , 102 , 104 , 105 , 108 - 110 , 118 , ...…”

Section: Reviewmentioning

confidence: 99%

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

show abstract

Section: Reviewmentioning

confidence: 99%

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…According to Bhutta et al the peptide RLS-0071 with the sequence IALILEPICCQERAA-dPEG24 is an inhibitor of the complement pathway and modulates neutrophil activation [22]. This peptide was recently developed for the treatment of acute lung injury in COVID-19 patients and was evaluated in a phase I clinical trial (USA) with 42 participants; it was estimated to finish in July 2021 [23].…”

Section: Regain Homeostasismentioning

confidence: 99%

Peptides in COVID-19 Clinical Trials—A Snapshot

Hilpert

2021

Biologics

View full text Add to dashboard Cite

Since the beginning of the COVID-19 pandemic, there has been a strong drive and desire to find effective treatments for and protection against the disease. On the webpage ClinicalTrials.gov, a total of 6505 clinical trials currently (September 2021) investigating various aspects of COVID-19 are registered. Of these, 124 studies involving peptides were identified. These 124 were further evaluated, and 88 trials that used peptides only for routine diagnostics were excluded. The remaining 36 trials were classified into 5 different classes according to their function: immunomodulatory (5 trials), regain homeostasis (10 trials), diagnostics/biomarkers (8 trials), vaccination (9 trials), and antiviral activity (4 trials, all overlap with immunomodulatory activities). In the current review, these 36 trials are briefly described and tabularly summarised. According to the estimated finish date, 14 trials have not yet finished. All of the finished trials are yet to report their results. Seven trials were based in the USA, and Egypt, France, the UK, Turkey, and the Russian Federation conducted three trials each. This review aims to present a snapshot of the current situation of peptides in COVID-19 clinical trials and provides a template to follow up on trials of interest; it does not claim to be a complete overview.

show abstract

“…Current treatments for Kaposi’s sarcoma are addressed, especially drugs that combat the cancer itself [ 19 ]. We also present information on the search for novel antiherpetics [ 20 , 21 , 22 ] to combat infection with other human herpesviruses. However, none of the chemotherapeutic interventions discussed deal with preventing a herpes infection.…”

mentioning

confidence: 99%